Monitoring SCCA‐IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis

Biasiolo, Alessandra; Chemello, Liliana; Quarta, Santina; Cavalletto, Luisa; Bortolotti, Flavia; Caberlotto, C; Beneduce, Luca; Bernardinello, Elisabetta; Tono, Natascia; Fassina, Giorgio; Gatta, Angelo; Pontisso, Patrizia

doi:10.1111/j.1365-2893.2007.00935.x

Cited by 37 publications

(47 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 SCCA isoforms have been found overexpressed in epithelial tumors, 20 primary liver cancer, [21][22][23] and chronically damaged hepatocytes. [24][25][26] The aim of this study was to assess the potential correlation between TGF-b1 and SERPINB3 in chronically damaged human liver tissue and to determine their relationship using in vitro models of cultured cells transfected with vectors expressing SERPINB3.…”

mentioning

confidence: 99%

SERPINB3 modulates TGF-β expression in chronic liver disease

Turato

Calabrese

Biasiolo

et al. 2010

Laboratory Investigation

View full text Add to dashboard Cite

Transforming growth factor-b1 (TGF-b1) is the master cytokine in the pathogenesis of liver fibrosis. TGF-b1 and extent of fibrosis were correlated recently to the serpin SERPINB3 in idiopathic pulmonary fibrosis, a chronic disease recalling liver cirrhosis. The aim of this study was to assess the relation between SERPINB3, TGF-b1 and fibrosis in chronic liver diseases and to determine the effect of this serpin on TGF-b1 expression using in vitro models. SERPINB3 and TGF-b1 were evaluated in liver biopsies of 94 patients with chronic liver disease. The effect of SERPINB3 on TGF-b1 expression was determined in primary human hepatocytes, HepG2 and Huh7 cells transfected with intact SERPINB3 human gene or with reactive site loop deleted mutants. A significant correlation between TGF-b1 and SERPINB3 at the protein level was observed in liver biopsies, confirmed by a positive correlation at mRNA level. Both proteins were correlated to the extent of liver fibrosis. All transfected cells showed increased TGF-b1 mRNA and protein production and the integrity of the reactive site loop of the serpin was crucial to achieve this effect. In conclusion, chronically damaged hepatocytes produce SERPINB3 and TGF-b, and the anti-protease activity of this serpin might be implicated in TGF-b1 induction.

show abstract

mentioning

confidence: 99%

SERPINB3 modulates TGF-β expression in chronic liver disease

Turato

Calabrese

Biasiolo

et al. 2010

Laboratory Investigation

View full text Add to dashboard Cite

show abstract

“…After a median period of six years, the same patients underwent a second liver biopsy and an increased level of the immune-complex was observed in 75% of cases with progressive disease (defined as an increase in fibrosis score ≥ 2 during follow-up in untreated patients). On the other hand, SCCA-IgM levels were substantially stable in patients with no disease progression during the same interval, and no difference in the level of the biomarker was detected in regard to the etiology of chronic liver disease [44] . In chronic HCV infection the presence of non-alcoholic steatohepatitis (NASH) at the histological level reflects a more severe clinical and pathological state than steatosis alone, being associated with a more rapid progression of fibrosis [45] .…”

Section: Scca-igm In Hcv-positive Patientsmentioning

confidence: 90%

“…The clinical usefulness of monitoring SCCA-IgM immune-complexes in chronic liver disease has been evaluated in several studies. In 2008 Biasiolo et al [44] observed that SCCA-IgM was detectable, at presentation, in 33% of untreated patients with histologically proven chronic hepatitis, but not in healthy control subjects. After a median period of six years, the same patients underwent a second liver biopsy and an increased level of the immune-complex was observed in 75% of cases with progressive disease (defined as an increase in fibrosis score ≥ 2 during follow-up in untreated patients).…”

Section: Scca-igm In Hcv-positive Patientsmentioning

confidence: 99%

“…The first evidence of the behavior of SCCA-IgM during antiviral treatment with PEG-IFN and ribavirin was obtained from a longitudinal study in 2010 [48] . Giannini et al [48] demonstrated that in patients with HCVrelated cirrhosis who achieved sustained virological [44] Significant increase of SCCA-IgM levels over time in 75% of untreated patients with chronic hepatitis and with histologically proven liver disease progression (fibrosis score increase ≥ 2) after six years of follow-up Martini et al [46] In patients with chronic hepatitis C, SCCA-IgM was found an independent predictor of histologically proven non alcoholic steatohepatitis SCCA-IgM and antiviral treatment Giannini et al [48] In chronic hepatitis C treatment with standard therapy, only patients who achieved sustained viral response showed a significant decrease in median values of SCCA-IgM up to one year of follow-up Fransvea et al [49] Reduction of SCCA-IgM levels during the first month of standard antiviral therapy was an independent predictor of sustained viral response Martini et al [46] Significant reduction of SCCA-IgM, lasting up to 6 mo of follow-up, was observed only in HCV-positive patients with sustained response to standard therapy SCCA-IgM in diagnosis and prognosis of HCC Pontisso et al [51] Significant increase over time of SCCA-IgM only in patients with early cirrhosis (histologically proven) who developed HCC within four years of follow up Buccione et al [52] In HCV-positive patients with overt cirrhosis, SCCA-IgM negativity (cut off ≤ 200 AU/mL) accurately identified patients at low risk of liver cancer development in the subsequent year Beneduce et al [24] SCCA-IgM showed higher sensitivity for the diagnosis of HCC, compared to AFP Pozzan et al [53] In patients with HCC, SCCA-IgM levels were found an independent predictor of survival. A reduction in SCCA-IgM levels was correlated with response to HCC treatment HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; AFP: Alpha-fetoprotein; SCCA-IgM: Squamous cell carcinoma antigen-immunoglobulins M.…”

Section: Scca-igm and Antiviral Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C

Martini

Gallotta

Pontisso

et al. 2015

WJH

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is the main cause of chronic liver disease and cirrhosis in Western countries. Over time, the majority of cirrhotic patients develop hepatocellular carcinoma (HCC), one of the most common fatal cancers worldwide -fourth for incidence rate. A high public health priority need is the development of biomarkers to screen for liver disease progression and for early diagnosis of HCC development, particularly in the high risk population represented by HCV-positive patients with cirrhosis. Several studies have shown that serological determination of a novel biomarker, squamous cell carcinoma antigen-immunoglobulins M (SCCA-IgM), might be useful to identify patients with progressive liver disease. In the initial part of this review we summarize the main clinical studies that have investigated this new circulating biomarker on HCV-infected patients, providing evidence that in chronic hepatitis C SCCA-IgM may be used to monitor progression of liver disease, and also to assess the virological response to antiviral treatment. In the last part of this review we address other, not less important, clinical applications of this biomarker in hepatology. Core tip: A high public health priority need is the development of biomarkers to screen for liver disease progression in hepatitis C virus (HCV)-positive patients. Serological squamous cell carcinoma antigen-immunoglobulins M has shown the ability to identify patients with progressive liver disease and patients at higher risk of hepatocellular carcinoma development. In this review we summarize the main clinical studies performed using this new circulating biomarker for monitoring cirrhosis progression in HCV-positive patients and to evaluate virological response to antiviral treatment. Clinical applications of squamous cell carcinoma antigenimmunoglobulins M to monitor chronic hepatitis C Martini A, Gallotta A, Pontisso P, Fassina G. Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C. MINIREVIEWS

show abstract

“…Recently, an ELISA assay has been developed to detect SCCA isoforms (SERPINB3 and SERPINB4) complexed with natural IgM in human serum [19]. Monitoring SCCA-IgM levels over time appears to be a useful approach to identify patients with viral chronic hepatitis at higher risk for cirrhosis development [20]. Significant reduction of SCCA-IgM, lasting up to 6 months of follow-up, was observed only in HCV-positive patients with a sustained response to standard therapy [21].…”

Section: Introductionmentioning

confidence: 99%

SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy

et al. 2019

View full text Add to dashboard Cite

Background: Non-alcoholic fatty liver disease (NAFLD) has a high prevalence in obesity and its presence should be screened. Laparoscopic sleeve gastrectomy (LSG) is an effective treatment for obesity, but its effects on NAFLD are still to be firmly established. The diagnosis of non-alcoholic steatohepatitis (NASH) is currently performed by liver biopsy, a costly and invasive procedure. Squamous cell carcinoma antigen-IgM (SCCA-IgM) is a biomarker of viral hepatitis to hepatocellular carcinoma development and its role in NAFLD to NASH progression has not yet been investigated. Objective: The aim of this study was to evaluate SCCA-IgM as a non-invasive biomarker of NAFLD/NASH in patients with different degrees of metabolic-complicated obesity before and after LSG. Method: Fifty-six patients with obesity were studied before and 12 months after LSG; anthropometric, biochemical, clinical, and imaging data were collected. Results: At baseline steatosis was strongly associated with the glycaemic profile (p = 0.016) and was already present in prediabetic patients with obesity (82%). Only 3 patients had an SCCA-IgM level above the normal cut-off. SCCA-IgM titre did not change according to glycaemic profile or steatosis. Metabolic and inflammatory factors and transaminases significantly reduced after LSG-induced weight loss, except for SCCA-IgM. The ALT/AST ratio decreased post-LSG correlated with BMI (r = 0.297, p = 0.031), insulin (r = 0.354, p = 0.014), and triglycerides (r = 0.355, p = 0.009) reduction. Conclusions: Our results confirm the tight link between NAFLD and metabolic complications, suggesting prediabetes as a new risk factor of steatosis. SCCA-IgM does not seem to have a role in the identification and prognosis of NAFLD.

show abstract

Monitoring SCCA‐IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis

Cited by 37 publications

References 23 publications

SERPINB3 modulates TGF-β expression in chronic liver disease

SERPINB3 modulates TGF-β expression in chronic liver disease

Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C

SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy

Contact Info

Product

Resources

About